[recIndex] (https://github.com/johnnybender/adastandards2016/blob/master/index/recIndex.md)

### **In patients with long-standing suboptimally controlled type 2 diabetes and established atherosclerotic cardiovascular disease, empagliflozin or liraglutide should be considered as they have been shown to reduce cardiovascular and all-cause mortality when added to standard care. Ongoing studies are investigating the cardiovascular benefits of other agents in these drug classes.**
* Unique ID: rec136
* Evidence Letter: B
* Category Name: PHARMACOLOGIC THERAPY FOR TYPE 2 DIABETES
* Page: S65
* Feasible: Yes
* Type: Rec
* Comments: 

#### Race Codes:

Description | Codes
----------- | -----


#### Ethnicity Codes:

Description | Codes
----------- | -----
|

#### ICD-9 Codes:

Description | Codes
----------- | -----
|

#### ICD-10 Codes:

Description | Codes
----------- | -----
|

#### ICD-10 PCS Codes:

Description | Codes
----------- | -----
|

#### SNOMED Codes:

Description | Codes
----------- | -----
|

#### CPT Codes:

Description | Codes
----------- | -----
|

#### HCPCS Codes:

Description | Codes
----------- | -----
|

#### LOINC Codes:

Description | Codes
----------- | -----
|

#### CVX Codes:

Description | Codes
----------- | -----
|

#### AHFS Medication Class:

Description | Codes
----------- | -----
|

#### RxNorm:

Description | Codes
----------- | -----
|

#### Miscellaneous Codes:

Description | Dictionary | Codes
----------- | ---------- | -----
|

#### Modules:

Module |
------ |
|

#### Implementation:
